Awiqli, the Once-Weekly Basal Insulin: Why It’s Interesting, What to Consider, and Why Support Still Matters
Awiqli, the first FDA-approved once-weekly basal insulin for adults with type 2 diabetes, could change how some people approach insulin therapy. Here’s what makes it interesting, the pros and cons to consider, and why support tools and care-team conversations still matter.
A Practical, Patient-Centered Guide to GLP-1 Medications for Diabetes Management
If you’re ready to start a GLP-1 Receptor Agonist Medication, here’s some background on how and why they work.
